However, while they are effective in subsets of patients with CD33+ AML or CD22+ B-ALL, respectively [7,8,9,10,11,12], others do not meaningfully benefit from these drugs as they are currently used. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.